TriangleDISEASE & TREATMENT SETTING
Urothelial Carcinoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Urothelial Carcinoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 30 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
- source wording
- Source null
16 more-specific settings
Balversa: metastatic Urothelial carcinoma with FGFR3 stated without a specific alteration, FGFR2 stated without a specific alteration (neoadjuvant) after prior therapy →Bavencio: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy →Keytruda: metastatic Urothelial carcinoma →Opdivo: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy →Imfinzi: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy →Tecentriq: metastatic Urothelial carcinoma with PD-L1 stated without a specific alteration →Tecentriq: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy →BALVERSA: metastatic Urothelial carcinoma with FGFR3 stated without a specific alteration after prior therapy →OPDIVO: Urothelial carcinoma (adjuvant) after prior therapy →OPDIVO: unresectable metastatic Urothelial carcinoma (first-line) →KEYTRUDA: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy →BAVENCIO: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy →BAVENCIO: metastatic Urothelial carcinoma (first-line) →OPDIVO: metastatic Urothelial carcinoma →KEYTRUDA QLEX: metastatic Urothelial carcinoma (neoadjuvant) after prior therapy →OPDIVO QVANTIG: Urothelial carcinoma (adjuvant) after prior therapy →
Study evidence for this setting
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Cabozantinib for Advanced Urothelial Cancer
A Study of TAS-120 in Patients With Advanced Solid Tumors
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Indication-specific source history
2016-05-18 · Tecentriq (atezolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-31dc52ae222b7841
- event date
- 2016-05-18
- event kind
- accelerated-approval
- drug or regimen
- Tecentriq (atezolizumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-7d51c53736e62185c4ca
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-02-02 · Opdivo (nivolumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-b239bd5494e43d88
- event date
- 2017-02-02
- event kind
- accelerated-approval
- drug or regimen
- Opdivo (nivolumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma that: • progressed during or following platinum-containing chemotherapy • progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-21ee45b733c6a87cf78e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-04-17 · Tecentriq (atezolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-cf4e2ee79af48174
- event date
- 2017-04-17
- event kind
- accelerated-approval
- drug or regimen
- Tecentriq (atezolizumab)
- source indication text
- Patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 as determined by an FDA approved test or who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-38ce38148faf9b6b853e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-05-01 · Imfinzi (durvalumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-de41e61c002720c8
- event date
- 2017-05-01
- event kind
- accelerated-approval
- drug or regimen
- Imfinzi (durvalumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9a149eb8f1a0aaa7a29d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-05-09 · Bavencio (avelumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-02e05b18b3dd774e
- event date
- 2017-05-09
- event kind
- accelerated-approval
- drug or regimen
- Bavencio (avelumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma following diease progression on platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-aaca0cfbb06dd4d4c78a
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2017-05-18 · Keytruda (pembrolizumab) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-5d0f55acd24475d7
- event date
- 2017-05-18
- event kind
- accelerated-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy 1
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-33a16a88396541f428d6
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2019-04-12 · Balversa (erdafitinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-1e0a7ad7f7cd910c
- event date
- 2019-04-12
- event kind
- accelerated-approval
- drug or regimen
- Balversa (erdafitinib)
- source indication text
- Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:susceptible FGFR3 or FGFR2 genetic alterations, andprogressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-d169b265eb06db35a234
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-06-30 · Bavencio (avelumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-d3df2da92772aad0
- event date
- 2020-06-30
- event kind
- traditional-approval
- drug or regimen
- Bavencio (avelumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma following diease progression on platinum-containing chemotherapy or disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-aaca0cfbb06dd4d4c78a
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-02-19 · Imfinzi (durvalumab) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-55247b6c363e12e6
- event date
- 2021-02-19
- event kind
- withdrawal
- drug or regimen
- Imfinzi (durvalumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-9a149eb8f1a0aaa7a29d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-04-13 · Tecentriq (atezolizumab) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-d28510f376f345a0
- event date
- 2021-04-13
- event kind
- withdrawal
- drug or regimen
- Tecentriq (atezolizumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma that progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-7d51c53736e62185c4ca
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-08-19 · Opdivo (nivolumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-19112ddc1f035eaa
- event date
- 2021-08-19
- event kind
- traditional-approval
- drug or regimen
- Opdivo (nivolumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma that: • progressed during or following platinum-containing chemotherapy • progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-21ee45b733c6a87cf78e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-08-31 · Keytruda (pembrolizumab) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-c1c3905e1b90eb57
- event date
- 2021-08-31
- event kind
- traditional-approval
- drug or regimen
- Keytruda (pembrolizumab)
- source indication text
- Locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy 1
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-33a16a88396541f428d6
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-12-02 · Tecentriq (atezolizumab) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-957b8b4619005b51
- event date
- 2022-12-02
- event kind
- withdrawal
- drug or regimen
- Tecentriq (atezolizumab)
- source indication text
- Patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 as determined by an FDA approved test or who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-38ce38148faf9b6b853e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-01-19 · Balversa (erdafitinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- event id
- fda-fccebc7550440d54
- event date
- 2024-01-19
- event kind
- traditional-approval
- drug or regimen
- Balversa (erdafitinib)
- source indication text
- Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:susceptible FGFR3 or FGFR2 genetic alterations, andprogressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA.
- match phrase
- urothelial carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-d169b265eb06db35a234
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-urothelial-carcinoma
- binding id
- ncit-C4030
- source collection
- ncit-concept
- source key
- C4030
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice